Research and Markets: In February 2008, a Dutch Court Ruled against Us Drug-Maker Pfizer in a Court Case Regarding the Patent on Atorvastatin
2008-07-16 05:20:00
DUBLIN, Ireland–(EMWNews)–Research and Markets (http://www.researchandmarkets.com/research/c55724/netherlands_pharma)
has announced the addition of the “Netherlands Pharmaceuticals and
Healthcare Report Q2 2008” report to their offering.
The Netherlands Pharmaceuticals and Healthcare Report provides
independent forecasts and competitive intelligence on Netherlands
pharmaceuticals and healthcare industry.
Growth will be far from impressive for the drug market in the
Netherlands over the forecast period, although, in many ways this
reflects the general sluggishness seen in mature markets. BMI expects
the market to reach a value of US$7.06bn in 2012, representing a
compound annual growth rate (CAGR) of 2.08%. Growth will be strongest in
the generics market but should also be reasonable for consumer health
products as these medicines benefit from government liberalisation
policies.
The generics sector, however, will be negatively impacted by the new
transition agreement regarding pharmaceutical prices that has come into
effect. In January 2008, the price of generic medicines was reduced by
10%. BMI has factored this decrease into our forecasts and believes that
the generics market will reach a value of US$1.28bn by 2012. In
addition, medicines whose patents expire in 2008 will see price cuts of
50%. The Dutch Pharmacy Association, KNMP, claims that the plans are
designed to keep the cost of medicines down. Also, they are designed to
help transform the pharmaceutical market from being supply-based to
being demand-based.
In terms of company activity, the sector has been quiet after last year
saw US drug-maker Schering-Plough acquire Organon, the pharmaceuticals
division of Dutch industrial conglomerate Akzo Nobel for EUR11bn
(US$14.5bn). However, in February 2008, a Dutch court ruled against US
drug-maker Pfizer in a court case regarding the patent on atorvastatin,
the key ingredient in cholesterol reducing drug Lipitor is invalid. This
is a severe blow for Pfizer, as it could open the door for generic
competition for its bestselling drug.
Meanwhile, recent attacks by animal extremists in the Netherlands have
forced a local company to pull out of a life sciences project. BMI
believes that the latest problems in the Netherlands, if sustained, will
have a negative impact on the country’s Business Environment Rating. The
Netherlands has a respected regulatory system, with an average score of
eight across our three main indicators, but we will downgrade the scores
if intimidation of the research sector is permitted to continue.
Key Topics Covered:
Executive Summary
Netherlands Pharmaceuticals And Healthcare Industry
Pharmaceutical Business Environment Ratings
Table: Western European Pharmaceutical Business Environment Ratings
Limits To Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement
OTC Medicines
Industry Developments
Healthcare Sector
Healthcare Insurance
Table: Key Points – Dutch Health Insurance Act, January 1 2006
Health Profile
Pharmaceuticals Sector
Recent Domestic Companies’ Activities
Recent Foreign Companies’ Activities
Research And Development Sector
Industry Forecast Scenario
Overall Market Forecast
Table: The Netherlands Drug Market Forecast Indicators
Key Growth Factors – Industry
Table: Netherlands Health Expenditure Indicators
Key Growth Factors – Macroeconomic
Table: Netherlands – Macroeconomic Forecasts
Patented Market Forecast
Table: The Netherlands’ Patented Drug Market
Forecast Indicators (US$mn unless otherwise stated)
Over-The-Counter Market Forecast
Table: The Netherlands OTC Drugs Market Forecast Indicators (US$mn
unless otherwise stated)
Generics Forecasts
Table: The Netherlands’ Generics And Branded
Market Forecast Indicators
Export/Import Forecasts
Table: The Netherlands’ Pharmaceutical Trade
Forecast Indicators (US$mn)
Key Risks To our Forecast Scenario
Competitive Landscape
Company Profiles
Leading Multinational Manufacturers
– Merck & Co
– Pfizer
– GlaxoSmithKline (GSK)
– Sanofi-Aventis
– Novartis
Indigenous Manufacturers
– Akzo Nobel
– DSM
– Qiagen
– Pharming Group
– Crucell
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
For more information visit http://www.researchandmarkets.com/research/c55724/netherlands_pharma
Research and Markets 646-607-1907 |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions